Eisen in der Therapie der Anämie bei Nierenkrankheit

Zusammenfassung

Eisenmangel ist ein wesentlicher Faktor, der bei chronischer Nierenerkrankung (CKD) zur Anämie beiträgt und die Lebensqualität einschränkt. Während die orale Eisensubstitution einfach durchführbar ist, erreicht man das Therapieziel vielfach nur sehr langsam. Niedrige Eisenresorptionsquoten bei Menschen mit CKD machen die Präparate wenig attraktiv, zusätzlich schränken gastrointestinale Nebenwirkungen die Adhärenz ein. Intravenöse Eisenpräparate sind in vielen Fällen deutlich effizienter, nebenwirkungsarm und sicher anwendbar; bei renaler Anämie soll ein Substratmangel behoben sein, bevor andere Medikamente zur Behandlung der Anämie gegeben werden. Im Jahr 2025 wird die aktualisierte Leitlinie der KDIGO zum Management der Anämie bei CKD erwartet. Wir zeigen Eckpunkte der vorab online publizierten Review-Fassung auf und legen aktuelle Konzepte der Diagnostik des Eisenmangels sowie der Eisensubstitutionstherapie dar.

Publication History

Article published online:
21 May 2025

• Literatur

• 1 Camaschella C. Iron-Deficiency Anemia. N Engl J Med 2015; 372: 1832-1843
• 2 Wong MMY, Tu C, Li Y. et al. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 2020; 13: 613-624
• 3 Iimori S, Naito S, Noda Y. et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTEstudy. Nephrology 2015; 20: 601-608
• 4 Fishbane S, Pollack S, Feldman HI. et al. Iron Indices in Chronic Kidney Disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 2009; 4: 57-61
• 5 Minutolo R, Locatelli F, Gallieni M. et al. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013; 28: 3035-3045
• 6 KDIGO. KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD). Public Review Draft. Stand: 2024 Im Internet: Accessed February 16, 2025 at: https://kdigo.org/wp-content/uploads/2024/11/KDIGO-2025-Anemia-in-CKD-Guideline_Public-Review-Draft_Nov42024.pdf
• 7 Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014; 29: 263-273
• 8 KDIGO. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Stand: 2012 Im Internet: Accessed February 16, 2025 at: http://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf
• 9 Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities]. Schweiz Med Wochenschr 1970; 100: 301-303
• 10 Labor Suhl. Eisendefizitrechner. Im Internet: Accessed February 16, 2025 at: https://www.labor-suhl.de/laborrechner/labor-rechner/berechnung-des-eisenbedarfs-nach-ganzoni/
• 11 Kang S-H, Kim B-Y, Son E-J. et al. Association between Iron Status and Survival in Patients on Chronic Hemodialysis. Nutrients 2023; 15: 2577
• 12 Macdougall IC, White C, Anker SD. et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2019; 380: 447-458
• 13 Coyne DW, Kapoian T, Suki W. et al. Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation. J Am Soc Nephrol 2007; 18: 975-984
• 14 Stoffel NU, von Siebenthal HK, Moretti D. et al. Oral iron supplementation in iron-deficient women: How much and how often?. Mol Aspects Med 2020; 75: 100865
• 15 Hallberg L, Ryttinger L, Söllvell L. Side-Effects of Oral Iron Therapy a double-blind study of different iron compounds in tablet form. Acta Med Scand 1966; 180: 3-10
• 16 Cook J. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18: 319-332
• 17 Cook J, Reddy M. Efficacy of weekly compared with daily iron supplementation. Am J Clin Nutr 1995; 62: 117-120
• 18 Umanath K, Jalal DI, Greco BA. et al. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol 2015; 26: 2578-2587
• 19 Wang C, Graham DJ, Kane RC. et al. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA 2015; 314: 2062
• 20 Auerbach M, Ballard H. Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety. Hematology 2010; 2010: 338-347
• 21 Muñoz M, Gómez-Ramírez S, Besser M. et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017; 15: 422-437
• 22 Macdougall IC, Bircher AJ, Eckardt K-U. et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 89: 28-39
• 23 McDonagh TA, Metra M, Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023; 44: 3627-3639
• 24 Kalra PR, Cleland JGF, Petrie MC. et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022; 400: 2199-2209
• 25 von Haehling S, Arzt M, Doehner W. et al. Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 2021; 23: 92-113
• 26 Aapro M, Beguin Y, Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv96-iv110
• 27 Macdougall IC, Bhandari S, White C. et al. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. J Am Soc Nephrol 2020; 31: 1118-1127